(Lead PI of the Administrative Core and Proteomics Core) is the director of QBI and a leader in connecting systems approaches with mechanistic insight to unravel basic biology of pathogens, such as SARS-CoV-2, HIV, zika, Ebola and dengue. He has led numerous large, collaborative center grants from NIH on a variety of different diseases, f
(Lead PI of the Administrative Core and Proteomics Core) is the director of QBI and a leader in connecting systems approaches with mechanistic insight to unravel basic biology of pathogens, such as SARS-CoV-2, HIV, zika, Ebola and dengue. He has led numerous large, collaborative center grants from NIH on a variety of different diseases, from HIV to cancer, and spearheaded the QCRG in early 2020, recruiting scientists from all over the world to study and combat COVID-19.
(Lead PI of the Protein Biochemistry Core and Structural Biology Core) is a world-recognized crystallographer with major contributions to structure-based drug design, the study of membrane proteins and HIV integrase and viral proteases.
(Lead PI of the In Vitro Virology Core and In Vivo Virology Core) is the director of the Gladstone Institute of Virology and recognized for her contributions to HIV Cure research and the pathogenesis of hepatitis C virus, zika virus and SARS-CoV-2 infections.
(Lead PI of the In Vivo Virology Core and In Vitro Virology Core) is the director of one of five NIAID-funded Centers of Excellence for Influenza Research and Surveillance and an expert on the molecular biology of negative-strand RNA viruses.
(Lead PI of the Proteomics Core) is a junior faculty at UCSF, an expert in mass spectrometry and Director of the Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery located at UCSF/Gladstone.
(Co-I of Project 2, Project 4, Project 5, the Screening Core, and Medicinal Chemistry Core) is an expert in molecular docking, structure-based inhibitor discovery and artifact detection in early discovery.
(Co-I of Project 1 and the In Vitro Virology Core) is a Nobel laureate renowned for the discovery of CRISPR and RNA-protein studies.
(Co-I of Project 2) is an expert in antiviral drug discovery and his crystal structures of HIV-1 RT drove the development of two anti-HIV drugs, etravirine and rilpivirine.
(Co-I of the In Vitro Virology Core) is recognized for generating recombinant arenaviruses, influenza and zika viruses with plasmid-based reverse genetic approaches. His lab has access to a maximum containment BSL-4 laboratory.
(Co-I of Project 2) is the world leader in characterizing the inhibition mechanisms of remdesivir and molnupiravir and focuses on studying and targeting RNA viral replication, with applications to Ebola, Nipah, Lassa, RSV, and influenza.
(Co-I of Project 4) focuses on developing new high throughput biophysical and biochemical characterization and screening methods to discover selective inhibitors of methyltransferases.
(Co-I of the In Vitro Virology Core) was recently ranked in the top 5 female NIH-funded investigators and studies innate immune evasion by coronaviruses, zika, HIV, influenza, chikungunya and dengue using human primary cell systems.
(Co-I of the Medicinal Chemistry Core) is an internationally recognized medicinal chemist and chemical biologist with over 20 years of experience in small-molecule drug discovery.
(Co-I of Project 2) is an expert in developing high-throughput, quantitative methods to assess genetic perturbations in primary cell models of infection.
(Co-I of the In Vivo Virology Core) studies influenza replication for target discovery and works towards generation of a universal influenza vaccine.
(Co-I of the In Vivo Virology Core) studies the replication, pathogenesis, transmission, and adaptation of respiratory viruses to new hosts.
(Co-I of Project 5) is the President of the UCSF Helen Diller Family Comprehensive Cancer Center and an expert in ADP-ribosylation signaling, advancing the concept of synthetic lethality to the clinic with his work on PARP inhibitors.
(Co-I of Project 1) made numerous breakthrough discoveries in translational machinery and is, with Kevan Shokat, the scientific founder of eFFECTOR, a company testing the selective translation inhibitor zotatifin in patients with mild-to-moderate COVID-19.
(Co-I of the Integrative Modeling Core) develops new approaches to address core challenges in systems pharmacology, such as elucidation of multitarget small-molecule mechanisms and delineation of pharmacological circuits.
(Co-I of the Integrative Modeling Core) studies the evolutionary dynamics and functional importance of post-translational regulatory networks and how they are rewired in the context of infection.
(Co-I of the In Vitro Virology Core) uses expertise in molecular virology, cell biology and advanced imaging to understand the cell biology of viral infection.
(Co-I of the In Vitro Virology Core and Administrative Core) is a senior scientist and the Project Manager of QBI’s infectious disease portfolio, with expertise in molecular virology and immunomodulation during infection.